Martin Shkreli, the American hedge fund manager and entrepreneur was criticized when Turing Pharmaceuticals obtained the manufacturing license for Daraprim, an out-of-patent medicine, and raised its price by 5,455 percent (from $13.50 to $750 per tablet). Was Martin’s 5,455% price increase on a life saving drug a great move financially as an entrepreneur, or was it unethical & wrong?Curious to hear reactions to this move...